Navamedic

Regulatory Filings • Nov 6, 2024

Navamedic launches Eroxon[®] in Finland

Navamedic launches Eroxon[®] in Finland

Oslo, 6 November 2024 - Building on the successful product launch of Eroxon[®]

in Norway and Sweden earlier this year, Navamedic ASA (OSE: NAVA), a Nordic

pharma company and reliable provider of high-quality products to hospitals and

pharmacies, is now launching Eroxon[®] across pharmacies in Finland. Eroxon[®]

will be the first clinically proven over-the-counter topical treatment for the

treatment of erectile dysfunction in men in Finland.

Eroxon[®] is part of Navamedic's increasingly growing Consumer Health category.

Since the product launched in Norway in February 2024, Eroxon[®] has already

become one of the top performing products within this category, and it is

expected to continue driving further growth. The product launch in Finland marks

the third launch this year and will be followed by a launch in Denmark in 2025.

The Finnish market for erectile dysfunction has significant potential. A recent

study[ [1]] concluded that 37 per cent of Finnish men above 18 years of age,

more than 800,000 men, have had first-hand experience with erectile dysfunction.

Two in three of these men had previously sought help to medically treat the

condition, indicating that men in Finland have a higher willingness to treat the

condition than their neighbours in other Nordic countries.

"Eroxon[®] is a fast-acting, safe, and easily accessible product designed to

help men enhance their sexual health and overall quality of life. With a

significant number of men in Finland experiencing erectile dysfunction and

showing interest in effective treatment options, we see strong market potential

for Eroxon[®] in supporting their health and well-being," said Jack Spira,

Medical Director at Navamedic.

Eroxon[®] offers a range of features which differentiates it from other forms of

treatments for erectile dysfunction. It is an effective and fast-acting gel

which typically helps men get an erection within ten minutes of application. It

has a good safety profile due to its local effect with no systemic absorption.

Eroxon[®] is approved as a treatment for erectile dysfunction in the EU and the

US.

[1] About the study

A total of 1,576 Finns aged 18 and over responded to the Eroxon® survey, which

was conducted in September-October 2024 (25/9-1/10/2024). The results are

weighted to be representative of the population. The number of respondents

varies by question. The survey was conducted by Taloustutkimus Oy. The maximum

margin of error for the entire respondent population is +/- 2.7 percentage

points.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to

empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and

requirements of the countries where we are present. Our local insight and

competence enable us to understand the specific needs of each country where we

operate and ultimately to gain market access. This makes us a preferred partner

for international companies expanding their footprint across the Nordics and

Benelux regions, through either in-licensing or out-licensing. Navamedic has

been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is

headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.